JEENA SIKHO LIFECARE LTD
NSE: JSLLMarket Closed • NSE
Day range
52 week range
JEENA SIKHO LIFECARE LTD closed at INR388.30 (-0.1%) on volume 0.66x its 20-day average, trading 53.5% below its 52-week high.
2026-Q2
Q2 FY2026 Financial Results
PAT moved +46.7% QoQ
2026-09-21
DIVIDEND Announced
Dividend - Rs 4.50 Per Share
2025-09-22
DIVIDEND Announced
Dividend - Re 1.10 Per Share
Revenue and PAT bars use independent scales to make their year-on-year direction readable.
Complete reported financial history · Values use the company's reporting currency
Hover over the chart for exact reported values. Percentage lines use the right-hand axis.
A 0–100 quantitative summary of reported fundamentals. Use the underlying financials and risks for context; the score is not a buy or sell recommendation.
Strengths
Strong Capital Efficiency: ROCE stands at 64.4%
Low Debt Profile: Debt-to-Equity is comfortable at 0.27x
High Cash Flow Conversion: CFO/PAT averaged 1.14x over last 3 years
Risks
Subject to cyclical raw material and macro industry pressures
Bull case
Market Leadership: Established operational scale in Medical Care Facilities.
Bear case
Macro Headwinds: Fluctuations in interest rates and sector-specific policy shifts could compress multiples.
Flip condition
Sustained quarterly EBITDA margin expansion above 20% would trigger an upgrade.
Complete dividend, bonus, split, rights and other action history
| Record date | Corporate action | Information | Announcement date | Ex-date |
|---|---|---|---|---|
| 21 Sept 2026 | Dividend | ₹4.50 / share | — | 21 Sept 2026 |
| 22 Sept 2025 | Dividend | ₹1.10 / share | — | 22 Sept 2025 |
Traded volume and delivery percentage across the latest 20 sessions
Compare valuation, latest quarterly performance and year-on-year growth
| Company name | Market cap ₹ Cr | P/E ratio | Dividend yield % | Quarterly sales ₹ Cr | Profit after tax ₹ Cr | Sales growth % | Profit growth % |
|---|---|---|---|---|---|---|---|
 Sun Pharmaceutical Industries LimitedSUNPHARMA Open analysis | ₹4.22L | 34.90 | 0.91% | ₹15,300.00 | ₹2,901.00 | +10.46% | +26.52% |
 Divi's Laboratories LimitedDIVISLAB Open analysis | ₹2.43L | 82.97 | 0.33% | ₹3,080.00 | ₹902.00 | +27.80% | +65.50% |
 Torrent Pharmaceuticals LimitedTORNTPHARM Open analysis | ₹1.73L | 72.83 | 0.83% | ₹4,128.00 | ₹389.00 | +41.90% | -21.89% |
 Apollo Hospitals Enterprise LimitedAPOLLOHOSP Open analysis | ₹1.13L | 54.32 | 0.25% | ₹7,044.00 | ₹610.00 | +20.58% | +38.32% |
 Zydus Lifesciences LimitedZYDUSLIFE Open analysis | ₹1.12L | 25.03 | 0.09% | ₹8,017.00 | ₹990.00 | +21.95% | -34.91% |
 LENSKART SOLUTIONS LTDLENSKART Open analysis | ₹1.12L | 174.73 | 0.00% | ₹2,714.00 | ₹228.00 | +43.29% | +273.77% |
 Laurus Labs LimitedLAURUSLABS Open analysis | ₹1.11L | 101.83 | 0.12% | ₹2,026.31 | ₹367.60 | +29.10% | +125.49% |
 Cipla LimitedCIPLA Open analysis | ₹1.07L | 31.78 | 0.98% | ₹7,119.00 | ₹786.00 | +2.33% | -39.16% |
Jeena Sikho Lifecare is one of the leading ayurvedic healthcare system providers in India. The company is providing healthcare services for the last ten years.
IndiaHealthcare
Is JEENA SIKHO LIFECARE LTD Shariah compliant?
JEENA SIKHO LIFECARE LTD is currently screened as Shariah Compliant under AAOIFI Shariah Standard No. 21. Business activities align with Shariah permissible sectors. Debt to Market Cap (2.64%) complies with AAOIFI threshold (≤ 33%).
What is JEENA SIKHO LIFECARE LTD's current valuation relative to peers?
JEENA SIKHO LIFECARE LTD trades at a P/E of 20.5x compared to the sector median of 37x, and a Price-to-Book of 10.3x.
Is the company financially healthy?
The company has a Debt-to-Equity ratio of 0.27x. Interest coverage is 23.5x.
What are the historical revenue and profit growth rates?
Over the past 5 years, revenue compounded at 11.3% while net profit growth averaged 22.6%.
Market data is informational and may be delayed. Shariah screening follows the displayed methodology. This is not investment advice.
Market data may be delayed. Quote date: 2026-10-16. Financial figures relate to their stated reporting periods. This information is for research and is not a recommendation to buy or sell.